Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) are exquisitely sensitive to imatinib. Almost all patients achieve a complete molecular remission (CMR) by nested reverse transcription polymerase chain reaction, which can be maintained with low-dose imatinib (eg, 3 × 100...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Metzgeroth, Georgia, Schwaab, Juliana, Naumann, Nicole, Jawhar, Mohamad, Haferlach, Torsten, Fabarius, Alice, Hochhaus, Andreas, Hofmann, Wolf-Karsten, Cross, Nicholas C. P., Reiter, Andreas
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2020
Aiheet:
Stimulus Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013256/
https://ncbi.nlm.nih.gov/pubmed/31995156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001111
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia